Benign Migratory Glossitis Associated With Antiangiogenic Drugs

Oral clinical descriptions related to adverse events in patients treated with those elective multi-targeted receptor tyrosine kinase inhibitors and a recombinant humanised monoclonal antibody

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cancer Geographic Tongue Glossitis Glossitis, Benign Migratory Mouth Diseases Neoplasms Stomatognathic Diseases Tongue Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Instituto do Cancer do Estado de São Paulo

São Paulo, 01246-000, Brazil

About this study

Electronical medical and dental records, high-resolution digital photograph were reviewed. Demographic data, medical background, clinical and laboratory information were recorded for each individual case.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patient's charts which underwent antiangiogenic targeted drugs

Exclusion criteria

chemoterapy without angiogenesis inhibitors

Treatment and study plan

Clinical evaluation

Other

treatment methods, associated symptoms, evolution and clinical presentation

Other names: clinical images

Primary outcomes

Benign migratory glossitis

Time frame: From enrollment to the end of study at 7 years

erythematous erosions, with loss of filiform papillae, surrounded by white circinate rims on the dorsal tongue

Secondary outcomes

Adverse events

Time frame: From enrollment to the end of study at 7 years

Dysgeusia , dermatologic toxicities such as skin erythemas and vesicles on the palms of the hands and burning sensation

Sponsors and collaborators

Lead sponsor

Instituto do Cancer do Estado de São Paulo

Other

Registry information

Official study title

Benign Migratory Glossitis Associated With Antiangiogenic Drugs Used in Cancer Treatment

Important dates

Study start: 2017
Primary completion: 2020
Study completion: 2024
First posted: May 25, 2025
Registry last updated: May 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed